Talimogene laherparepvec (T-VEC) combined with ipilimumab was more effective in treating advanced melanoma than either treatment alone, report Igor Puzanov, MD, of Vanderbilt University Medical Center in Nashville, Tenn., and coauthors.
In a phase Ib trial of 19 patients with advanced melanoma, the results showed that 50% had positive responses to the combined immunotherapy, and 44% had durable responses lasting 6 months or longer. At 18 months, 50% of patients showed no progression, and overall patient survival was 67%, the authors reported.
The study’s safety analysis showed no new signs of safety concerns, or of any dose-limiting toxicities.
Read the full study in The Journal of Clinical Oncology.